By Meagan Fitzpatrick, Postmedia News July 16, 2010
Kidney cancer patients in Ontario have scored a victory with the province's recent decision to fund a critical drug treatment and patient advocates are hoping the remaining provinces that don't cover its cost will soon follow suit.
Because radiation and chemotherapy are ineffective in treating kidney cancer when it has spread to other parts of the body, what are known as targeted therapies with drugs are crucial to prolonging...
Medistem Panama Founder Granted US Patent on Cancer Treatment Based on Patient's Own Cells
SAN DIEGO, CA--(Marketwire - July 6, 2010) - Medistem Inc. (PINKSHEETS: MEDS). Medistem Panama, licensee of Medistem Inc., announced today issuance of US patent # 7,749,495 covering a new method for treating cancer that does not require use of chemotherapy or radiation. The procedure, which involves taking out patient cells, manipulating them, and re-introducing...
Rosetta Genomics and Collaborators Demonstrate MicroRNAs Accurately Sub-Classify Renal Tumors
Study published in The Journal of Molecular Diagnostics
REHOVOT, Israel & PHILADELPHIA--(BUSINESS WIRE)--Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that a peer-reviewed article entitled “Accurate Molecular Classification of Renal Tumors...
LONDON (Reuters) - Novartis AG's cancer drug Afinitor has been rejected for patients with kidney cancer by Britain's health costs watchdog, which says it is too pricey for the country's taxpayer-funded National Health Service (NHS).
The drug, known generically as everolimus, was being considered for the second line treatment of advanced renal cell carcinoma, but the National Institute for Health and Clinical Excellence (NICE) said it...
Phase III Study Shows Novartis Drug Afinitor® More Than Doubles Time Without Tumor Growth In Advanced Pancreatic NET Patients
Article Date: 03 Jul 2010 - 1:00 PDT
Novartis Pharmaceuticals Corporation ("Novartis") announced that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine...
